Sang Cheul Oh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2647123/publications.pdf

Version: 2024-02-01

66 4,243 26 61 papers citations h-index g-index

66 66 6248
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 2461-2471.	6.3	1,749
2	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clinical Cancer Research, 2017, 23, 4441-4449.	3.2	342
3	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology. The, 2022, 23, 234-247.	5.1	268
4	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. Cancer Cell, 2014, 26, 77-91.	7.7	252
5	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 2020, 23, 510-519.	2.7	155
6	Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. Clinical Cancer Research, 2015, 21, 357-364.	3.2	127
7	Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Letters, 2019, 447, 12-23.	3.2	106
8	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer, 2021, 24, 946-958.	2.7	61
9	Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer. Cell Death and Disease, 2019, 10, 846.	2.7	60
10	BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation. Tumor Biology, 2015, 36, 9475-9486.	0.8	54
11	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 143-153.	2.7	45
12	Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells. Tumor Biology, 2016, 37, 9709-9719.	0.8	43
13	RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer. Cell Death and Differentiation, 2020, 27, 676-694.	5.0	43
14	Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports. Korean Journal of Radiology, 2014, 15, 494.	1.5	42
15	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clinical Cancer Research, 2016, 22, 6228-6235.	3.2	40
16	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1045-1056.	5.1	39
17	Genipin inhibits the invasion and migration of colon cancer cells by the suppression of HIF- \hat{l} ± accumulation and VEGF expression. Food and Chemical Toxicology, 2018, 116, 70-76.	1.8	37
18	RUNX3 inhibits the metastasis and angiogenesis of colorectal cancer. Oncology Reports, 2016, 36, 2601-2608.	1.2	35

#	Article	IF	Citations
19	Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 581-589.	1.4	35
20	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: AÂrandomised phase III trial. European Journal of Cancer, 2020, 130, 51-62.	1.3	34
21	Novel Systemic Therapies for Advanced Gastric Cancer. Journal of Gastric Cancer, 2018, 18, 1.	0.9	33
22	Docosahexaenoic Acid Enhances Oxaliplatin-Induced Autophagic Cell Death via the ER Stress/Sesn2 Pathway in Colorectal Cancer. Cancers, 2019, 11, 982.	1.7	33
23	Changing strategies for target therapy in gastric cancer. World Journal of Gastroenterology, 2016, 22, 1179.	1.4	32
24	Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF- $1\hat{l}_{\pm}$ in human glioma stem cells. Oncotarget, 2017, 8, 40233-40245.	0.8	31
25	RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer. Oncogene, 2019, 38, 3903-3918.	2.6	30
26	Gliomaâ€derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Reports, 2017, 18, 150-168.	2.0	29
27	Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics, 2019, 9, 2235-2251.	4.6	28
28	Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients. PLoS ONE, 2017, 12, e0176834.	1.1	26
29	Activating CCT2 triggers Gli-1 activation during hypoxic condition in colorectal cancer. Oncogene, 2020, 39, 136-150.	2.6	26
30	Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation <i>via</i> Mule in colorectal cancer cells. Oncotarget, 2016, 7, 59503-59518.	0.8	26
31	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). Oncologist, 2019, 24, 18-e24.	1.9	25
32	PARK7 modulates autophagic proteolysis through binding to the N-terminally arginylated form of the molecular chaperone HSPA5. Autophagy, 2018, 14, 1870-1885.	4.3	23
33	Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer. Cancers, 2019, 11, 642.	1.7	22
34	Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation. International Journal of Biochemistry and Cell Biology, 2017, 89, 147-156.	1.2	20
35	Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. BioMed Research International, 2016, 2016, 1-14.	0.9	19
36	Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. International Journal of Biochemistry and Cell Biology, 2018, 102, 128-137.	1.2	19

#	Article	IF	Citations
37	Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin. Tumor Biology, 2015, 36, 8819-8829.	0.8	18
38	Update of Adjuvant Chemotherapy for Resected Gastric Cancer. Journal of Gastric Cancer, 2012, 12, 3.	0.9	17
39	Hedgehog signaling pathway as a potential target in the treatment of advanced gastric cancer. Tumor Biology, 2017, 39, 101042831769226.	0.8	17
40	Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. OncoTargets and Therapy, 2018, Volume 11, 4233-4246.	1.0	17
41	Diallyl disulfide (DADS) boosts TRAIL-Mediated apoptosis in colorectal cancer cells by inhibiting Bcl-2. Food and Chemical Toxicology, 2019, 125, 354-360.	1.8	17
42	Cannabidiol Suppresses Angiogenesis and Stemness of Breast Cancer Cells by Downregulation of Hypoxia-Inducible Factors-1l±. Cancers, 2021, 13, 5667.	1.7	17
43	Genipin increases oxaliplatin-induced cell death through autophagy in gastric cancer. Journal of Cancer, 2020, 11, 460-467.	1.2	16
44	Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 751-761.	1.9	14
45	Codium fragile F2 sensitize colorectal cancer cells to TRAIL-induced apoptosis via c-FLIP ubiquitination. Biochemical and Biophysical Research Communications, 2019, 508, 1-8.	1.0	13
46	TRAILâ€Induced Caspase Activation Is a Prerequisite for Activation of the Endoplasmic Reticulum Stressâ€Induced Signal Transduction Pathways. Journal of Cellular Biochemistry, 2016, 117, 1078-1091.	1.2	11
47	Imatinibâ€ʻinduced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress. Oncology Reports, 2018, 41, 1616-1626.	1.2	11
48	Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein. Journal of Vascular Access, 2017, 18, 345-351.	0.5	10
49	Anatomical distribution and detection rate of colorectal neoplasms according to age in the colonoscopic screening of a Korean population. Annals of Surgical Treatment and Research, 2018, 94, 36.	0.4	10
50	Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean Journal of Internal Medicine, 2020, 35, 171-184.	0.7	10
51	Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells. Korean Journal of Internal Medicine, 2021, 36, S196-S206.	0.7	9
52	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer, 2022, 25, 207-217.	2.7	9
53	Deficiency of 15-LOX-1 Induces Radioresistance through Downregulation of MacroH2A2 in Colorectal Cancer. Cancers, 2019, 11, 1776.	1.7	7
54	Prognostic implication of systemic inflammatory markers in young patients with resectable colorectal cancer. Annals of Surgical Treatment and Research, 2021, 100, 25.	0.4	7

#	Article	IF	CITATIONS
55	NK/T-Cell Lymphoma Associated with Epstein-Barr Virus in a Patient Infected with Human Immunodeficiency Virus: An Autopsy Case. International Journal of Hematology, 2004, 79, 480-483.	0.7	6
56	Korean Red Ginseng Extract Increases Apoptosis by Activation of the Noxa Pathway in Colorectal Cancer. Nutrients, 2019, 11, 2026.	1.7	5
57	Prognostic significance of interim ¹⁸ Fâ€fluorodeoxyglucose positron emission tomography–computed tomography volumetric parameters in metastatic or recurrent gastric cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e302-e309.	0.7	4
58	Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist, 2021, 26, e414-e424.	1.9	4
59	Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor?. Translational Gastroenterology and Hepatology, 2016, 1, 3-3.	1.5	2
60	Effects of the proximity of metastasis to the central vessels of the liver on surgical outcomes and survival in colorectal cancer with liver metastasis. ANZ Journal of Surgery, 2021, 91, E183-E189.	0.3	1
61	Clinical Implication of Tumor Markers. Korean Journal of Medicine, 2012, 83, 197.	0.1	1
62	Preoperative Chemotherapy in Advanced Stomach Cancer (Cons). Journal of Gastric Cancer, 2008, 8, 65.	0.9	1
63	Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population. Journal of Human Genetics, 2007, 52, 668-674.	1.1	O
64	The Effect of Telomerase Antisense for the Differentiation of Embryonic Stem Cells to Hemopoietic Stem Cells Blood, 2004, 104, 4201-4201.	0.6	0
65	Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease. The Korean Journal of Hematology, 2007, 42, 335.	0.7	O
66	Metastasis to the Iliopsoas Muscle from Advanced Gastric Carcinoma: an Unusual Site of Metastasis. Korean Journal of Medicine, 2012, 82, 754.	0.1	0